---

---

Agenda

Visit CDER Small Business and Industry Assistance Page

ABOUT THIS EVENT

Pharmaceutical quality assures the availability, safety, and efficacy of every dose of medicine. Everyone deserves confidence in their next dose of medicine. Problems with pharmaceutical quality can impact the availability of medicine to patients and consumers. The mission of CDER’s Office of Pharmaceutical Quality (OPQ) is to assure quality medicines are available to the American public. This symposium, held every two years, will explore topics related to pharmaceutical quality regulation, supply chains, and advanced manufacturing technologies. Attendees will become familiar with the regulatory quality assessment, inspection, policy, surveillance, and research activities that impact the pharmaceutical supply chain and assure drug quality.

Learn more about the FDA’s pharmaceutical quality toolbox. OPQ’s quality assessment of drug applications uses tools that streamline risk assessment and knowledge management. OPQ policy conveys the most current thinking on pharmaceutical quality topics to enable manufacturers to provide high-quality drugs. Market surveillance and enforcement tools work to support the health of pharmaceutical supply chains while protecting the public. Programs focused on advanced pharmaceutical manufacturing provide tools for regulators and drug developers so that patients and consumers can benefit from promising new technologies. This pharmaceutical quality toolbox helps assure that quality medicines are available to the American public.

INTENDED AUDIENCE

• Manufacturing professionals focused on drug products, including new drug applications (NDAs), abbreviated new drug applications (ANDAs) and biologics license applications (BLAs) marketed in the U.S. and regulated by CDER
• Regulatory affairs professionals interested in FDA’s pharmaceutical quality policy and surveillance programs
• Foreign regulators and other international bodies interested in pharmaceutical quality harmonization
• Healthcare professionals and others interested in medicine quality, the U.S. supply chain, and advanced pharmaceutical manufacturing technologies

TOPICS COVERED

• Quality assessment of drug product marketing and licensing applications and how it relates to FDA innovations and facility evaluations
• Pharmaceutical quality policy and how new domestic and international efforts drive toward improved quality outcomes for patients and consumers
• Pharmaceutical supply chains and how FDA market surveillance activities help to assure drug quality
• Advanced pharmaceutical manufacturing technologies and how FDA is preparing for industry’s use of technologies such as AI for pharmaceutical manufacturing

FDA RESOURCES

• Protecting Patients & Consumers from Drug Quality Risks (video)
• FDA’s Office of Pharmaceutical Quality
• CDER’s Drug Quality Sampling and Testing Programs
• 2022 Report on the State of Pharmaceutical Quality
• Pharmaceutical Quality Resources
• Framework for Regulatory Advanced Manufacturing Evaluation
• Emerging Technology Program